Inhibition of vascular endothelial growth Factor‐A downregulates angiogenesis in psoriasis: A pilot study

Andrea Luengas‐Martinez,Dina Ismail,Ralf Paus,Helen S. Young
DOI: https://doi.org/10.1002/ski2.245
2023-05-17
Skin Health and Disease
Abstract:We report that vascular endothelial growth factor‐A (VEGF‐A) inhibition downregulates inflammatory angiogenesis in psoriasis plaque skin ex vivo. Our data suggest that anti‐angiogenic agents, which are used in oncology and ophthalmology, could be repurposed and integrated into the management of patients with psoriasis. We also explore whether patients with severe psoriasis and/or high levels of VEGF‐A in skin/plasma could benefit most from VEGF‐A blocking therapy. Background Vascular Endothelial Growth Factor (VEGF)‐A‐mediated angiogenesis participates in the pathogenesis of psoriasis, thus inviting the hypothesis that anti‐VEGF‐A therapy could be beneficial in psoriasis. While anti‐angiogenic agents are used in oncology and ophthalmology, these therapeutic strategies remain unexplored for the management of psoriasis. Objective Our objective was to investigate ex vivo how VEGF‐A blockade impacts blood vessels, epidermis and immune cells in organ‐cultured plaque and non‐lesional skin from patients with psoriasis. Methods Skin biopsies from patients with psoriasis (n = 6; plaque and non‐lesional skin) and healthy controls (n = 6) were incubated with anti‐VEGF‐A monoclonal antibody (bevacizumab, Avastin®) or a human IgG1 isotype control for 72‐h in serum‐free organ culture. CD31/LYVE‐1, Ki‐67, and mast cell tryptase expression were assessed by quantitative immunohistomorphometry. VEGF‐A levels in plasma, PBMCs and skin culture supernatants were measured. Results Inhibition of VEGF‐A blocked all free VEGF‐A ex vivo, reduced blood vessel area and the number of blood vessel endothelial cells in plaques of psoriasis (*p
What problem does this paper attempt to address?